Order Article Reprints

de la Rubia J, Alonso R, Clavero ME, Askari E, García A, Antón C, Fernández M, Escalante F, García A, Rios-Tamayo R, et al. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain. Cancers. 2023; 15(11):2964. https://doi.org/10.3390/cancers15112964

de la Rubia, Javier, Rafael Alonso, María Esther Clavero, Elham Askari, Alfonso García, Cristina Antón, Margarita Fernández, Fernando Escalante, Ana García, Rafael Rios-Tamayo, and et al. 2023. "Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain" Cancers 15, no. 11: 2964. https://doi.org/10.3390/cancers15112964

de la Rubia, J., Alonso, R., Clavero, M. E., Askari, E., García, A., Antón, C., Fernández, M., Escalante, F., García, A., Rios-Tamayo, R., Conesa, V., Bermúdez, M. A., Merchán, B., Velasco, A. E., Blanchard, M. J., Sampol, A., Gainza, E., Hernández, P. M., & Alegre, A. (2023). Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain. Cancers, 15(11), 2964. https://doi.org/10.3390/cancers15112964